DA
URGN icon

Denali Advisors’s UroGen Pharma URGN Stock Holding History

Denali Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,300
Closed -$200K – 509
2023
Q3 		$200K Sell
14,300
-4,700
-25% -$75.4K 0.07% 226
2023
Q2 		$197K Buy
+19,000
New +$210K 0.07% 215
2022
Q2 		– Sell
-4,100
Closed -$36K – 420
2022
Q1 		$36K Buy
+4,100
New +$32K 0.01% 273

Other funds holding URGN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Denali Advisors's URGN Position: Q4 2023 in Review

Denali Advisors sold out of UroGen Pharma (URGN) in Q4 2023, closing a stake of 14,300 shares — an estimated $200K sold.

Denali Advisors first reported a position in URGN in Q1 2022 and held it in 3 quarters. The position peaked at $200K in Q3 2023. 105 funds tracked by Wall St. Rank hold URGN as of Q4 2023.

  • Denali Advisors reported no remaining UroGen Pharma position as of Q4 2023 after selling out during the quarter.
  • Denali Advisors sold 14,300 UroGen Pharma shares in Q4 2023, an estimated $200K.
  • Denali Advisors first reported a position in UroGen Pharma in Q1 2022 and held it in 3 quarters.
  • Denali Advisors's UroGen Pharma position peaked at $200K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2023.

Based on Denali Advisors's 13F filing for Q4 2023, filed 19 Jan 2024.